PharmaMar KOL Event

June 10, 2020

General Agenda

Access event HERE: https://us02web.zoom.us/webinar/register/WN_VNUWp9BNRO2ZWb8-8FXd2A

Guest speaker Dr Hossein Borghaei (Fox Chase Cancer Center, Philadelphia and American Lung Association, Lung Cancer Expert Medical Advisory Panel) will discuss SCLC and Lurbinectedin.

RSVP to Patrick Till (ptill@troutgroup.com)

Agenda:

  • Small Cell Lung Cancer Disease Overview
  • Current Standard of Care – 1st and 2nd line treatments
  • Lurbinectedin Monotherapy data
  •  How Lurbinectedin will potentially be used in clinic
RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

PharmaMar SA [PHM:ES]
Yon­delis (soft tis­sue sar­co­ma and ovarian can­cer) com­mer­cial­ized with di­rect sales-force in EU and part­n­er­ship in US with Janssen. Signed li­cens­ing agree­ment with Jazz Phar­ma for Lur­binecte­din in the US - up­front pay­ment of $200M, $100mm on ap­pro­va­land up to $550M sales mile­s­tones. Jazz to launch Zepzel­ca in US Ju­ly 2020. [more in­for­ma­tion]